LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

Inicio・Lista de Acciones・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Cerrado

Sector Salud

1.87 11.31

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.84

Máximo

1.91

Métricas clave
By Trading Economics
Ventas	2M
BPA	-0.34
Empleados	405

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+46.28 upside

Dividendos
By Dow Jones
Próximas Ganancias	6 nov 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-2.3M 114M
Apertura anterior	-9.44
Cierre anterior	1.87

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

105 / 389 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

1.54 / 2 Soporte y Resistencia

Sangamo Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 nov 2024, 22:50 UTC

Acciones populares

Stocks to Watch: Nvidia, Intel, Sherwin-Williams, Dow, Nuwellis

1 nov 2024, 22:43 UTC

Principales Movimientos del Mercado

Nvidia, Sherwin-Williams Shares Up on Addition to DJIA

1 nov 2024, 22:13 UTC

Principales Movimientos del Mercado

Chewy Up 5% on S&P MidCap 400 Inclusion

1 nov 2024, 21:39 UTC

Ganancias

Insurance Company Chubb Projects Up to $300 Million Pre-Tax Loss on Hurricane

2 nov 2024, 13:53 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2 nov 2024, 13:44 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov 2024, 13:00 UTC

Ganancias

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2 nov 2024, 12:58 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov 2024, 12:48 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2 nov 2024, 12:32 UTC

Ganancias

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

2 nov 2024, 12:28 UTC

Adquisiciones, fusiones, absorciones

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov 2024, 12:17 UTC

Ganancias

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q EPS $18272.00 >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q BNSF Operating Earnings $1.38B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Berkshire Hathaway Energy Company Operating Earnings $1.63B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Insurance-Underwriting Operating Earnings $750M >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Other Operating Loss $877M >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Insurance-Investment Income Operating Earnings $3.66B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Net $26.25B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Other Controlled Businesses Operating Earnings $3.34B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Non-Controlled Businesses Operating Earnings $199M >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Operating Earnings $10.09B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Investment, Derivative Gains $16.16B >BRKA

2 nov 2024, 09:30 UTC

Principales Noticias

Awful Jobs Report Aside, the Economy Is Still Strong -- Heard on the Street -- WSJ

2 nov 2024, 08:20 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

2 nov 2024, 08:20 UTC

Charlas de Mercado

Ganancias

Auto & Transport Roundup: Market Talk

1 nov 2024, 22:51 UTC

Ganancias

Correction to Nvidia to Replace Intel in Dow Jones Industrial Average Article -- WSJ

1 nov 2024, 22:00 UTC

Principales Noticias

Ganancias

Nvidia to Replace Intel in Dow Jones Industrial Average. Sherwin-Williams Also Joins. -- WSJ

1 nov 2024, 21:29 UTC

Principales Noticias

Ganancias

Exxon and Chevron Feel Brunt of Cheaper Oil -- 2nd Update

1 nov 2024, 21:24 UTC

Ganancias

Insurance Company Chubb Projects Up to $300M Pre-Tax Loss on Hurricane

Comparación entre iguales

Cambio de precio

Sangamo Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

46.28% repunte

Estimación a 12 meses

Media 2.75 USD 46.28%

Máximo 5 USD

Mínimo 1 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sangamo Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para Sangamo Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.54 / 2Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

Sentimiento

By Acuity

105 / 389 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

EBITDA

Beneficio operativo

Acerca de Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company is focused on translating science into medicines that transform the lives of patients with serious diseases. Its product candidates include Giroctocogene fitelparvovec (SB-525), ST-920, SAR445136, ST-400 and TX200. Its SB-525, is a lead product candidate, a gene therapy for the treatment of hemophilia A. Its ST-920, is a gene therapy product candidate for the treatment of fabry disease. SAR445136, is its cell therapy product candidate for the treatment of sickle cell disease (SCD). Its ST-400 is a cell therapy product candidate for the treatment of transfusion dependent beta thalassemia. Its TX200, is a chimeric antigen receptor (CAR), engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection.